Main Uses and Benefits of Alectinib

Alectinib is generally used in clinical situations involving specific distressing symptoms linked to the underlying disease. It is commonly used for conditions characterized by periods of heightened symptoms, such as Non-Small Cell Lung Cancer (NSCLC) in patients with the ALK-positive mutation. It is considered relevant in clinical settings involving systemic disease, particularly where symptoms may intensify temporarily.

The primary benefit of this treatment is its role in symptomatic management within domains where additional support is required. By assisting with the therapeutic management of the condition, Alectinib helps ease the overall symptom burden. It may assist with managing symptoms related to increased neurological activity when the disease affects the Central Nervous System, and it supports the patient during episodes of heightened discomfort.

“This therapy is commonly used to help patients cope more steadily with symptom fluctuations associated with specific genetic forms of lung cancer.”

This support helps relieve symptoms related to systemic imbalance, which contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

Quick Fact: Support for Symptoms Related to Systemic Imbalance Alectinib is commonly used to help with symptoms that create noticeable physiological strain. This assists with maintaining functional stability when symptoms interfere with daily functioning.

Alectinib is indicated for use exclusively in adult patients with Anaplastic Lymphoma Kinase (ALK)-positive non-small cell lung cancer (NSCLC). This requirement is based on the official determination that its safety and efficacy have not been established in children and adolescents under 18 years of age.

Contraindications and Restrictions

Classification	Rule/Restriction (Official Labeling)
Absolute Contraindication	Patients with known hypersensitivity to alectinib or any of its excipients must not use the medicine [4.5].
Conditional Exclusion	Not for use in patients with rare hereditary problems, such as galactose intolerance or congenital lactase deficiency, due to the presence of lactose [1.4].
Organ Function Restriction	Use in patients with severe hepatic impairment (Child-Pugh C) requires a lower starting dose [3.1]. Use in severe renal impairment has not been established but does not typically require a starting dose change [1.2].

Pregnancy and Lactation: Alectinib is known to cause fetal harm based on animal studies [2.5]. Females of reproductive potential must use effective contraception during treatment and for a period after the last dose (5 weeks per US FDA, 3 months per EMA/Health Canada) [4.4]. Breastfeeding is not recommended [4.3].

Interactions with other medicines and products

Alectinib's official regulatory interaction profile is primarily defined by its co-administration rules and effects on drug transporters. The drug is a substrate of CYP3A4 metabolism, but clinical studies indicate no clinically meaningful change to overall exposure when co-administered with strong CYP3A inhibitors (like Posaconazole) or inducers (like Rifampin).

Similarly, Alectinib shows no clinically meaningful effect on the exposure of sensitive substrates for CYP3A (Midazolam) or CYP2C8 (Repaglinide), simplifying the management of these combinations. However, Alectinib and its active metabolite M4 are documented inhibitors of the efflux transporters P-glycoprotein (P-gp) and BCRP. Appropriate patient monitoring is recommended when co-administering Alectinib with substrates of these transporters.

A Clinically Significant Interaction exists with food, which significantly increases the drug's absorption and bioavailability (by approximately 3.1-fold). Due to this effect, the administration of Alectinib must be taken with food.

A potential pharmacodynamic interaction exists with medicinal products known to cause bradycardia (slow heart rate) or anti-hypertensive medications. If a patient develops symptomatic bradycardia, regulatory constraints require the evaluation of these concomitant products for potential adjustment.

Selective Blockade of the ALK Oncogenic Enzyme

Alectinib functions as a Tyrosine Kinase Blocker by selectively targeting the aberrant ALK fusion protein. The molecule engages in competitive binding within the ATP-binding pocket of the kinase domain. This molecular interaction prevents the enzyme's activation, which is the foundational step in inhibiting the malignant cell's constant growth signal, resulting in the physiological consequence of inhibiting the cellular mechanism.

Shutdown of Downstream Survival Pathways

The blockade of ALK prevents the subsequent activation of critical internal communication circuits, including the PI3K/AKT/mTOR and STAT3 signaling cascades. By shutting down these pro-survival pathways, the drug strips the malignant cell of the internal signals needed to live and multiply, forcing the cell to undergo apoptosis (programmed cell death), which acts to halt proliferation.

Central Nervous System (CNS) Access Mechanism

This domain details the drug's ability to overcome the blood-brain barrier (BBB). Alectinib's chemical structure prevents it from being ejected by the P-glycoprotein efflux pump, allowing for sustained drug retention within the CNS. This key mechanistic feature ensures the inhibitory action is effective against targeted cellular mechanisms in the brain and spinal cord, leading to a systemic distribution of the inhibitory effect.

Alectinib is administered exclusively by the oral route as a 150 mg hard capsule. The standard regimen for adults is 600 mg taken twice daily (BID), resulting in a total daily dose of 1200 mg. It is a mandatory administration condition that the medicine be taken with food to ensure correct absorption. The capsules must be swallowed whole and should not be opened, crushed, or dissolved.

Dosing is maintained for an extended period, depending on the therapeutic context. For the adjuvant setting, treatment is continued for a fixed duration of two years, or until disease recurrence. For the metastatic setting, the medicine is administered continuously until disease progression is observed or unacceptable toxicity develops.

Procedural rules define dosage adjustments and handling of missed timing. If a patient is unable to tolerate the standard dose, the dose may be lowered sequentially to 450 mg twice daily, and then to 300 mg twice daily. If a scheduled dose is missed, or if vomiting occurs, the patient must skip the dose and resume the regular schedule at the next designated time; no double doses should be taken. Furthermore, patients with severe hepatic impairment (Child-Pugh C) must begin treatment at a reduced starting dose of 450 mg twice daily.

Alectinib's clinical evidence is primarily derived from large, global Randomized Controlled Trials (RCTs) exploring its application across different stages of ALK-positive Non-Small Cell Lung Cancer (NSCLC).

Research in treatment-naïve metastatic disease utilized RCTs to compare Alectinib against a prior standard-of-care ALK inhibitor (crizotinib). These studies measured key outcomes such as the time lived without cancer progression (Progression-Free Survival, PFS) and Overall Survival (OS). A significant focus was placed on measurements of disease non-progression in the Central Nervous System (CNS). However, the long-term interpretation of OS data is complicated by treatment crossover, as many patients in the comparator group later switched to Alectinib, affecting the ability of the original trial to report absolute survival differences between the initial two strategies.

In the early-stage (adjuvant) setting following surgical tumor removal, a Phase 3 Controlled Trial explored the medicine versus standard chemotherapy, measuring Disease-Free Survival (DFS). While initial research reports observed measurements of DFS, the final Overall Survival (OS) outcomes are not fully established because the data are still considered immature. This means that long-term recurrence and survival patterns beyond the fixed two-year treatment period are still being monitored.

Alectinib was also studied for use in patients whose advanced disease progressed after prior treatment with crizotinib, relying on smaller Phase II and observational trials. Generally, comparative evidence for direct head-to-head comparisons of Alectinib against other modern ALK inhibitors is limited, and research remains ongoing to understand specific resistance patterns and address evidence gaps in special patient groups.

Common questions about Alectinib (FAQ)

Q: What is the main thing Alectinib is used for?

According to the official product information, Alectinib is indicated for the treatment of ALK-positive non-small cell lung cancer (NSCLC). It is approved for use both in the advanced (metastatic) setting and in the adjuvant setting, which means after the tumor has been surgically removed.

Q: Are there any dietary restrictions I need to follow while using Alectinib?

The official instructions mandate that this medicine be taken with food to support optimal absorption, as indicated in the instructions. Beyond this, medical professionals typically advise continuing a normal diet unless specific restrictions are provided by the prescribing physician.

Q: What is the risk of liver problems with Alectinib?

Official product information indicates that Alectinib can cause liver problems, which is known as hepatotoxicity. Increases in liver enzymes (ALT, AST) and bilirubin are common adverse reactions that may occur during treatment.

Q: Can Alectinib be used by people who have existing heart conditions?

Studies show that Alectinib may cause a slow heart rate, a condition called bradycardia. Because of this, official documents indicate that monitoring a patient's heart rate and blood pressure by a healthcare professional is part of the required treatment protocol.

Q: How does Alectinib affect the liver enzymes that doctors check?

Increases in liver enzymes like ALT and AST, as well as bilirubin, are common adverse reactions noted in studies. Regulatory documents specify that monitoring these enzymes using blood tests is a required part of the treatment protocol.

Q: What are the major contraindications for Alectinib?

The only absolute contraindication defined in regulatory documents is a hypersensitivity (severe allergic reaction) to the active substance, alectinib, or to any of the product's inactive ingredients (excipients).

Q: What is the average duration of response mentioned in clinical trials?

For patients receiving the medicine in the early-stage (adjuvant) setting, clinical research evidence indicates that the median Disease-Free Survival (DFS) had not yet been reached at the time of the primary analysis. This measure reflects how long patients lived without disease recurrence.

Q: Is Alectinib a form of chemotherapy or a different kind of treatment?

Official information describes Alectinib as a Tyrosine Kinase Inhibitor (TKI), which is a type of targeted therapy. This mechanism selectively targets the cancer-driving ALK fusion protein and is distinct from traditional, platinum-based chemotherapy.

Q: What are the most common side effects people talk about with Alectinib?

Official sources report that the most common side effects, affecting more than 2 in 10 people, include constipation, muscle pain, fatigue, swelling (edema), rash, and cough.

Q: Does Alectinib cause hair loss?

Official safety data reports that hair loss (alopecia) is not listed among the very common or common side effects observed in clinical trials for Alectinib.

Q: Can Alectinib affect my eyesight?

Yes, regulatory documents list visual disturbances as common side effects. These can include blurred vision, spots or floaters, reduced visual acuity, and double vision.

Q: Is it normal to feel tired when taking Alectinib?

Yes, official product information indicates that fatigue is a very common side effect reported by patients in clinical trials.

Q: What kind of routine monitoring is needed while on Alectinib?

Official guidelines indicate that monitoring several health metrics throughout treatment is required by the product label. This includes regular blood tests to check liver enzymes and muscle enzymes, as well as regular checks of heart rate and blood pressure.

Q: Does Alectinib interact with herbal supplements like St. John's Wort?

Official patient information states that a doctor should be informed about all herbal supplements taken during treatment, including St. John's Wort.

Q: Are there any specific activities or sun exposure risks while on Alectinib?

Yes, official safety information indicates that avoiding direct sunlight and using protective measures is necessary. This includes wearing protective clothing, sunglasses, and an SPF 50+ sunscreen during treatment and for 7 days after the last dose.

Q: Can women who are pregnant or breastfeeding use Alectinib?

Regulatory documents state the medicine may cause fetal harm. The regulatory label states that females of reproductive potential must use effective contraception during treatment and for 5 weeks afterward. Regulatory documents advise against breastfeeding during treatment and for 1 week after the last dose.

Q: Does Alectinib have an impact on fertility?

The regulatory label states that males must use effective contraception during treatment and for 3 months after the last dose.

Q: What should I do if I experience a severe skin rash while taking Alectinib?

Rash is noted as a common side effect in regulatory documents. The official guidance contained in the product label states that immediate consultation with a healthcare professional is necessary for any severe or worsening side effects or skin changes.

Q: Where can I find the official prescribing information for Alectinib?

The complete official prescribing information is typically published on the websites of regulatory bodies, such as the FDA (DailyMed) and the EMA (SmPC), as well as on the drug manufacturer's official labeling page.

Q: Can Alectinib interact with common over-the-counter medications?

Official patient information indicates that a doctor should be informed about all medicines taken, including those bought over the counter, vitamins, and supplements. This information is necessary for a complete review of potential interactions.

Q: What happens if Alectinib stops working for me?

Official administration conditions describe treatment as continuing until the disease progresses (stops responding) or until unacceptable toxicity develops. The treating physician evaluates these conditions to determine when to stop or adjust treatment.

Q: Is a low blood pressure reading common while taking Alectinib?

The regulatory label notes that bradycardia (a slow heart rate) is a common side effect. Monitoring of both heart rate and blood pressure by a healthcare professional is a required safety measure.

Q: How does Alectinib treatment compare to the placebo group in research studies?

Official regulatory overviews of the clinical evidence state that in key studies for advanced disease, Alectinib was often compared against another ALK inhibitor (crizotinib) or chemotherapy, but was not compared with a placebo (a dummy treatment).

Q: Are there different brand names for the medicine Alectinib?

Yes, the brand name for the medicine alectinib is Alecensa.

Q: Does Alectinib cause any problems with muscle aches or joint pain?

Yes, official safety reports list muscle pain (myalgia) and joint pain as common adverse reactions experienced by patients.

Q: Can Alectinib affect my blood sugar levels?

Official safety information indicates that high blood sugar levels (hyperglycemia) have been reported as a common metabolic side effect in clinical trials.

Q: Is it possible to have an allergic reaction to Alectinib?

Yes, official regulatory documents state that the medicine is contraindicated in patients with a known hypersensitivity (allergic reaction) to alectinib or any of the product’s inactive ingredients.

The official regulatory requirements for storing and disposing of Alectinib (Alecensa) capsules focus on environmental control and safety.

---

Storage Conditions

Alectinib must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with limited excursions permitted up to 30°C. The capsules must be kept in the original container and protected from light; the bottle must be kept tightly closed. For safety, the medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Alectinib, along with any waste material, must be disposed of according to local requirements. Official regulatory documents mandate that disposal should be carried out via an approved waste disposal plant as pharmaceutical waste. Contaminated residues must not be discharged into drains.